On the afternoon of July 24, 2023, Linaxin Biotechnology held a work summary meeting for the first half of 2023 at the group headquarters. The meeting aimed to summarize and review the company's work situation in the first half of the year, analyze the new problems currently faced, study and assign key work tasks for the second half of the year, and solidly promote the smooth completion of various annual goals and tasks.

At the meeting, each department and subsidiary conducted a detailed review and analysis of the achievements made in the past six months. At the same time, they also deeply analyzed the existing problems and shortcomings, and had thoughts and measures for the work in the second half of the year.

The work in the first half of 2023 is the result of the hard work and dedication of all employees. Whether it is the achievements or problems in the work, it is a valuable experience and wealth.

Dr. Tan Shengwei, General Manager of Linaxin Biotechnology, put forward "four requirements" for the work in the second half of the year:

Firstly, we must have strong confidence in stable growth and strictly adhere to the three lifelines of "signing contracts for delivery, receiving payments, and contributing funds".

Secondly, we must focus on practical implementation, zero excuses, zero delays, and zero arguments, and adhere to a results oriented approach.

Thirdly, we must ensure the implementation of excellent services, with customer needs at the center and customer satisfaction as the starting point.

Fourthly, strengthen safety inspections to eliminate potential safety hazards in their early stages and prevent them before they occur.

Finally, the general manager said, "I hope that in the second half of the year, everyone will focus on the annual work plan, identify and fill in the gaps, and continue to maintain a good development momentum. We should not only pay attention to increasing revenue and reducing expenses, but also focus on innovative development

The work summary meeting of Linaxin Biotechnology in the first half of 2023 not only demonstrated the company's recognition of past achievements, but also showcased their ambitious plans for future development. This summary meeting will inject new momentum into the business growth and innovation of Linaxin Biotechnology.